People With Haemophilia A Increased Flexibility in Their Daily Lives ( GLASGOW , Scotland , May 21 , 2018 PRNewswire = 연합뉴스 ) A new long term stability study has shown that haemophilia A treatment NovoEight ( R ) ( turoctocog alfa ) remains potent after three months exposure to temperatures of 40 º C . [ 1 ] The results were presented today at the WFH 2018 World Congress in Glasgow , UK . Treatment storage issues , especially the need for refrigeration , have been shown to be a common problem reported by people with haemophilia A . [ 2 ] A portability study recently published in Patient Preference and Adherence found that most people are restricted in their personal activities , particularly travel and sports , due to temperature storage issues . [ 2 ] If efficacy and safety are unaffected , storage flexibility was shown to be a strong driver of product choice . [ 2 ] " Establishing the stability of NovoEight ( R ) up to 40 ° C is part of our commitment to helping people with haemophilia A to reduce the burden that this condition places on their lives , " said Mads Krogsgaard Thomsen , executive vice president and chief science officer , Novo Nordisk . " The recent data demonstrate the reliable nature of NovoEight ( R ) as a portable and convenient treatment option , which could help patients enjoy their daily lives without concern about the storage of their treatment . " The storage conditions for NovoEight ( R ) allows for it to be kept at temperatures of up to 40 º C for three months . [ 3 ] About the study This was a long - term stability study comparing the potency of NovoEight ( R ) stored at 5 º C for 30 months to NovoEight ( R ) stored at 5 º C for 27 months , then followed by storage at 40 ° C ± 2 ° C / 75 % relative humidity ( RH ) ± 5 % RH for three months . The potency of NovoEight ( R ) was maintained at high storage temperature and humidity conditions . The effect of repeated temperature changes was tested by storage at 5 ° C ± 3 ° C / ambient humidity / darkness for 24 months , followed by cycling between 5 ° C and 40 ° C / 75 % RH up to 10 times ; the product was then stored at 40 ° C / 75 % RH for three months ( resulting in a total of four months at 40 ° C ) , and returned to 5 ° C to attain 30 months shelf life . [ 1 ] The potency of NovoEight ( R ) was maintained at high storage temperature and humidity conditions . Up to 10 cycles of temperature changes and storage at 40 ° C did not affect potency . [ 1 ] About NovoEight ( R ) NovoEight ( R ) is a B - domain truncated recombinant human coagulation factor VIII for the treatment and prevention of bleeding in patients with haemophilia A . [ 3 ] About haemophilia A Haemophilia is a chronic , inherited bleeding disorder that primarily affects males . People with haemophilia A are either missing or have a malfunctioning factor VIII protein , which is needed for proper blood clotting . People with haemophilia A have a tendency to bleed longer than most or to bleed internally into joints , muscles or organs because they are missing this clotting factor . To manage the disease and stop bleeding , people with haemophilia A must replace the missing factor VIII protein , which is accomplished by intravenous injection of the clotting factor . [ 4 ] Globally , it is estimated that 150 , 000 people have been diagnosed with haemophilia A . [ 5 ] The disease is severely underdiagnosed in developing countries . About Novo Nordisk Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care . This heritage has given us experience and capabilities that also enable us to help people defeat obesity , haemophilia , growth disorders and other serious chronic diseases . Headquartered in Denmark , Novo Nordisk employs approximately 42 , 700 people in 79 countries and markets its products in more than 170 countries . For more information , visit novonordisk . com , Facebook [ http : / / www . facebook . com / novonordisk ] , Twitter [ http : / / www . twitter . com / novonordisk ] , LinkedIn [ http : / / www . linkedin . com / company / novo - nordisk ] , YouTube [ https : / / www . youtube . com / novonordisk ] . References 1 . Turoctocog alfa is stable during storage at 40 ° C and multiple sequences of temperature cycling , poster # 52 . Presented at the WFH 2018 World Congress , Glasgow , UK , 21 May 2018 . 2 . Tischer B , Marino R , Napolitano M . Patient preferences in the treatment of hemophilia A : impact of storage conditions on product choice . Patient Preference and Adherence . 2018 ; 12 : 431 - 441 3 . NovoEight ( R ) Summary of Product Characteristics , April 2018 4 . Srivastava A , Brewer AK , Mauser - Bunschoten EP , et al . Guidelines for the management of hemophilia . Haemophilia . 2013 ; 19 : e 1 - 47 5 . World Federation of Hemophilia . Report on the Annual Global Survey 2016 . Published October 2017 . Available online at : http : / / www 1 . wfh . org / publications / files / pdf - 1690 . pdf . Last accessed April 2018 . Further information Media : Katrine Sperling + 45 - 4442 - 6718 krsp @ novonordisk . comAsa Josefsson + 45 - 3079 - 7078 aajf @ novonordisk . comInvestors : Peter Hugreffe Ankersen + 45 - 3075 - 9085 phak @ novonordisk . comAnders Mikkelsen + 45 - 3079 - 4461 armk @ novonordisk . comChristina Kjær + 45 - 3079 - 3009 cnje @ novonordisk . comSource : Novo Nordisk [ 편집자 주 ] 본고 는 자료 제 공사 에서 제공 한 것 으로 , 연합뉴스 는 내용 에 대해 어떠 한 편집 도 하 지 않 았 음 을 밝혀 드립니다 . ▶ 기사 제보 및 문의 ▶ 내 생활 에 흥 이 나 는 최신 트렌드    ▶ 사진 구매 문의